Endonovo Therapeutics Inc Stock OTC Bulletin Board
Equities
US4111551044
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2023 | Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
2023 | Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval | CI |
Financials (USD)
Sales 2021 | 0.07 | Sales 2022 | 0.14 | Capitalization | 3.5M |
---|---|---|---|---|---|
Net income 2021 | -3M | Net income 2022 | -18M | EV / Sales 2021 | 112,421,804 x |
Net Debt 2021 | 7.1M | Net Debt 2022 | 7.15M | EV / Sales 2022 | 78,689,579 x |
P/E ratio 2021 |
-0.3
x | P/E ratio 2022 |
-0.14
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 77.47% |
Managers | Title | Age | Since |
---|---|---|---|
Alan Collier
CEO | Chief Executive Officer | 59 | 12-02-29 |
Steven Barnes
IRC | Investor Relations Contact | - | 14-04-30 |
Corporate Officer/Principal | 68 | 22-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Collier
CEO | Chief Executive Officer | 59 | 12-02-29 |
1st Jan change | Capi. | |
---|---|---|
+20.03% | 126B | |
+23.61% | 117B | |
+23.26% | 27.52B | |
-18.07% | 20.87B | |
-15.13% | 17.01B | |
-14.81% | 16.26B | |
+9.78% | 14.56B | |
-46.10% | 15.09B | |
+52.34% | 13.89B |